Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00161785|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : May 21, 2015
The purpose of this study is to assess:
- TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT).
- TBE antibody response to a booster vaccination with FSME-IMMUN 0.5ml, by means of ELISA and NT.
|Condition or disease||Intervention/treatment||Phase|
|Tick-borne Encephalitis||Biological: FSME-IMMUN 0.5ml||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||340 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||June 2004|
|Study Completion Date :||July 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00161785
|Hospital in Debica - Zespo Opieki Zdrowotnej w Debicy|
|Debica, Poland, 33-200|
|Szpital Jana Pawla II Oddzial Neuroinfekcji|
|Krakow, Poland, 31-202|
|Principal Investigator:||Ryszard Konior, MD||Szpital Jana Pawla II Oddzial Neuroinfekcji, Krakow, Poland|